(redirected from recurrence risk)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to recurrence risk: Relative risk
References in periodicals archive ?
To check the robustness of our estimations, we develop an alternative measure of conflict recurrence risk without relying on the level and growth of domestic per capita income, presented in the second column of Table 1, and find that the estimated risk of conflict recurrence remains robust.
discussion of recurrence risk and risk reduction for the couple and close family.
The relative reduction in risk of local recurrence from adjuvant radiotherapy is constant in all age groups but the younger patient has a higher baseline recurrence risk.
For example, women younger than age 50 who were randomized to chemotherapy had a 49% reduction in recurrence risk through 4 years if they were ER-positive, and a similar 43% reduction if they were ER-poor.
Steps down the slippery slope to adoption without proper demonstration of utility can already be seen with tests purporting to identify those individuals of sufficiently low recurrence risk that particular adjuvant therapies (predominantly chemotherapy) may be avoided completely.
The treatment begins after final pathologic evaluation of margins, lymph nodes and other features that have an impact on recurrence risk.
A genetic evaluation will help define the prognosis, aid in management decisions, define accurate recurrence risk for the parents, and permit access to appropriate support groups.
Associations of VDR polymorphisms with recurrence risk were also evaluated.
If a termination has been carried out because of anomalies detected by ultrasound scan, by declining an autopsy parents will remain ignorant of information that might change the recurrence risk of one in four cases and have a one in 13 chance for missing confirmation of a high (one in four) recurrence risk.
Mothers who bear one child with such a defect run a 2 to 7 percent recurrence risk in each successive child, depending o n where in the world they live.
The Pharmacor Patient Flow Model for Ovarian Cancer, which utilizes Decision Resources' proprietary suite of epidemiological cancer models that include the modeling of recurrent cases of ovarian cancer, finds that--based on historical trends in recurrence risk as well as an increasing percentage of early-stage patients receiving drug treatment--the number of drug-treated early-stage cases that develop recurrent advanced disease will decrease by around 3 percent per year through 2031.